STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (March 2022)

30 slides from STRATA Skin Sciences's investor presentation, Mar 14, 2022

  1. Slide 1: Driving Value to Dermatology Partners Matching Patients with Clinics

    Investor Presentation December 2020 Investor Presentation March 2022 Driving Value to Dermatology Partners Matching Patients with Clinics

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,”

  3. Slide 3: Addressing large markets for chronic skin diseases

    3 Source: 1 Market Data Forecast Report 2021, Fortune Business Insights 2018, 2019 Addressing large markets for chronic skin diseases with differentiated laser-based treatments Recurring revenue model drives repeat and sustainable revenues Customer base of ~1K partner practices and growing Sales dri

  4. Slide 4: Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions

    Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions 4 CEOCFOVP MarketingVP of Professional RelationsDirector of Business Operations3 new Board Members New Leadership Commercial Focus and Execution Acquisitions DTC marketing analyticsDirect to dermatologist marketingPartner

  5. Slide 5: Large Unmet Need in Common and Chronic Dermatologic Conditions

    Large Unmet Need in Common and Chronic Dermatologic Conditions 5 ATOPIC DERMATITIS PSORIASIS VITILIGO PSORIASIS: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches (65% Mild; 25% Moderate; 10% Severe)~8 Million patients in the U.S.3 VI

  6. Slide 6: XTRAC Treatments by Indication – United States

    XTRAC® Treatments by Indication – United States 6 5% 80% 15% Opportunities exist for expanding use for other approved indicationsVitiligo Eczema (Atopic Dermatitis) #1use for XTRAC® lasers domestically Psoriasis treatments remain

  7. Slide 7: XTRAC: Psoriasis

    XTRAC®: Psoriasis 7 After 4 tx After 2 tx Baseline Clinical Protocol – 6.2 treatments to PASI 75 Beam of UVB light applied to the affected area PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trial

  8. Slide 8: XTRAC: Vitiligo

    XTRAC®: Vitiligo 8 Beam of UVB light applied to the affected area XTRAC®The solution for Vitiligo Results in re-pigmentation UVB light reduces the immune system’s attack on the melanocytes Simple, safe, effective + long-lastingExcimer laser Baseline After 18 tx After 29 tx

  9. Slide 9: Multicenter Psoriasis Study

    Multicenter Psoriasis Study7 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or better after 10

  10. Slide 10: Treatment Options Addressing Psoriasis Indication

    Treatment Options Addressing Psoriasis Indication6 10 XTRAC NB-UVB* Topical Steroids Non-biologic Systemics Biologics Approximate Costs ($) Cost competitive 1K-3K 3K-9K 1K -7K 1K 32K-68K Clinical Impact Better clinical outcomes (PASI%75) 92% 71% 75% 48% 50-70% Speed of Onset (in weeks) Very fast rat

  11. Slide 11: XTRAC is the Leader in Targeted 308nm Excimer Laser Therapy

    Best-in-class Excimer TREATMENT XTRAC® is the Leader in Targeted 308nm Excimer Laser Therapy 11 Safe & Effective Treatment 150+ Peer-Reviewed Clinical Studies Economical for Patients and Payors Win-Win for Providers and their Patients

  12. Slide 12: Growing Installed Base Drives Recurring Revenue Model

    Growing Installed Base Drives Recurring Revenue Model 12 01/01/19 Systems 12/31/19 1/01/20 12/31/20 Systems 12/31/21 01/01/21 Systems Net Installed Base Growth 2019-2021 25% growth in installed base over the last 3 years Actively redeploying under utilized devices Group and international placements

  13. Slide 13: A True Partnership – Delivering a Complete Business Solution

    A True Partnership – Delivering a Complete Business Solution 13 Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Assistance DTC Marketing

  14. Slide 14: Key Priority: Driving Commercial Execution

    Key Priority: Driving Commercial Execution 14 Sustain investment in DTC marketing Continue to focus and grow high-volume accounts Drive increased utilization across all indications Increase marketing to drive awareness among derms Historical trends show positive correlation between DTC investment an

  15. Slide 15: Domestic Market: Sales and Service Engine Overview

    Domestic Market: – Sales and Service Engine Overview4 Regions30 Sales Territories2 National Account Managers15 Field Service TechsIn-House Call Center to Qualify LeadsPredominant Provider of Excimer Laser Treatments 15 Territories color coded

  16. Slide 16: XTRAC Installed Base – Multiple Growth Drivers

    XTRAC® Installed Base – Multiple Growth Drivers International Current Markets: China, Japan, Saudi Arabia, S. Korea, IsraelInsurance covered in most marketsUsage per device higher than U.S. market1,300 devices sold and in service54 International partner XTRAC® clinics (up from 10 in 2019) 16 Expansi

  17. Slide 17: Acquired the U.S. Dermatology Business of Ra Medical Systems

    Acquired the U.S. Dermatology Business of Ra Medical Systems 17 Provides STRATA with the opportunity to market its full business solution to Ra Medical’s existing customer base of 250+ active accountsPositions STRATA as the predominant provider of excimer laser treatments in the U.S.Thru 12/31/2021

  18. Slide 18: Theraclear Acquisition

    Theraclear Acquisition 18 Substantially broadens STRATA’s opportunity with expansion potential into the estimated $5.5B acne care market Creates robust pipeline of opportunities to target conditions beyond acne with a unique light treatment approach Reinforces STRATA’s vision to be the premier provi

  19. Slide 19: Executive Management Team

    Executive Management Team: 100+ yrs. dermatology experience Robert (Bob) J. Moccia, CEO Encore Dermatology, Precision Dermatology, Medicis Pharmaceuticals, Graceway Pharmaceuticals, Bioglan Pharmaceuticals, Stiefel Laboratories, Dermik Laboratories (RPR) Chris Lesovitz, CFO Encore Dermatology, Iroko

  20. Slide 20: Fourth Quarter and Full Year 2021 Financial Highlights

    Fourth Quarter and Full Year 2021 Financial Highlights 20 Fourth Quarter and Full Year 2021 Financial HighlightsPreliminary, unaudited total revenue is expected to range from $8.8 million to $9.2 million, compared to $6.7 million in the fourth quarter of 2020Preliminary, unaudited total revenue for

  21. Slide 21: Commercial Drivers in 2022

    Commercial Drivers in 2022 21 Continue DTC advertising campaign with social media XTRAC® Awareness: Co-Op advertising to suitable patients (digital + print) Develop patient advocacy partnerships Broadened commercial strategy to expand use within partner practices Added emphasis on professional relat

  22. Slide 22: STRATA Key Investment Takeaways

    STRATA Key Investment Takeaways 22 Differentiated Treatment providing a Win-Win-Win for Patients + Clinics + Payers Addressing Large and Growing Markets +Positioned for Inorganic Growth Proven Business Model to Expand + Achieve Sustainable Results and Shareholder Returns

  23. Slide 23: Thank You

    Investor Presentation December 2020 Thank You

  24. Slide 24: Appendix

    Investor Presentation December 2020 Appendix

  25. Slide 25: Board of Directors

    Board of Directors William Humphries Chairman of the Board andGovernance & Compensation Committee CEO, Isosceles Pharmaceuticals, Inc. former President & Group Chairman Ortho Dermatologics, Merz Pharmaceuticals, Stiefel Pharmaceuticals, Allergan Pharmaceuticals Dr. Uri Geiger CEO Accelmed Inc. CEO E

  26. Slide 26: Financial Metrics

    Financial Metrics 26 * Total recurring revenue over total installed base** Company estimates not provided Unaudited quarterly results * See press release dated November 10, 2021 for definitions of non-GAAP measures 2018 Q1 '19 Q2 '19 Q3 '19 Q4 '19 2019 Q1 '20 Q2 '20 Q3 '20 Q4 '20 2020 Q1 '21 Q2'21 Q

  27. Slide 27: Partner Academic Institutions

    Partner Academic Institutions 27

  28. Slide 28: Strata Dermatology Markets Addressed

    Strata Dermatology Markets Addressed Psoriasis Eczema (Atopic Derm.) Vitiligo Acne 28 Psoriasis Treatment Market* Size (2019 to 2027)2019 Global Market Value of $20.1B USD 1Projected Market Value of $40.6B USD by 2027 1CAGR of 9.2% 2020-2027 1 Eczema Treatment Market* Size (2020 to 2026)2020 Global

  29. Slide 29: Growing Demand for Drug-Free Treatment Options

    Growing Demand for Drug-Free Treatment Options 29 Source: Dermatology Devices Report, Grand View Research 2021 Base year 2020, historic information 2016 to 2019, and forecast 2021 to 2028 USD Millions USD Millions $7.1B $34.1B $5.1B $993M Projected CAGR +21.2%2021-2028 Projected CAGR +19.9%2021-2028

  30. Slide 30: Footnotes

    Footnotes Company estimatesHistorical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultraviolet A; UVB, ultraviolet BNational Eczema As

STRATA Skin Sciences — Investor Presentation (March 2022) on 6ix